Customizing first-line BTK inhibitors for CLL

On October 23, 2024, 18:30−19:30 BST, the Lymphoma Hub will be pleased to present a virtual symposium: Customizing first-line BTK inhibitors for CLL. 

The chair, Gilles Salles, will be joined by expert speakers, Paolo Ghia and Francesc Bosch. This symposium aims to enhance understanding of the unmet needs associated with BTK inhibitors in CLL, the current and future perspectives of BTK inhibitors, and the optimal use of BTK inhibitors in clinical practice. After attending this symposium, participants will be able to describe novel therapeutic targets in CLL, explain the mechanisms of action for new agents, recall the latest data for new agents, including their regulatory status in CLL, describe the rationale for selecting such treatments based on previous treatments and patient-related factors, describe the adverse event profiles of novel agents, and state how adverse events could be managed in clinical practice. 

This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech., administered by Janssen Scientific Affairs, LLC. All content is developed by SES in collaboration with the faculty; funders are allowed no influence on the content of this activity. 

For more information, please visit Lymphoma Hub Virtual Symposium 

For free registration, please visit Register - Lymphoma Hub Virtual Symposium 

If you are interested in supporting a future Lymphoma Hub symposium, please contact our partnerships team for current opportunities at partnerships@scientificeducationsupport.com